Psilocybin or Nicotine Patch for Smoking Cessation A Pilot Randomized Clinical Trial
JAMA Network Open - Mar 10, 2026
2 domains / 4 areas / 2 specializations
Data updated
The Centre for Psychedelic and Consciousness Research focuses on how psychedelics affect behavior, cognition, brain function, and biological health markers. They have been at the forefront of demonstrating the safety and efficacy of psychedelics for mental disorders, expanding their focus into psilocybin research across multiple mental health conditions, including smoking cessation, major depressive disorder, and cancer-related anxiety.
Johns Hopkins sits at the research-led end of the psychedelic education field rather than the retreat or coaching market. It is best known for rigorous, evidence-based teaching from faculty who helped shape modern clinical psychedelic research, so it suits learners who want scientific literacy, clinical context, and a sober view of risks as well as promise. The public-facing course offering is broad rather than specialist, with notable lineage through the Johns Hopkins Center for Psychedelic and Consciousness Research and instructors including David Yaden, Frederick Barrett, Albert Garcia-Romeu, and Sandeep Nayak.
Best for curious members of the public, clinicians, and researchers who want a credible, university-backed introduction to psychedelic science and medicine. It is less about hands-on facilitation and more about understanding the evidence base, ethics, and clinical landscape.
No formal prerequisites are stated for the public Coursera course. Johns Hopkins faculty bios indicate that the content is grounded in clinical and research expertise, but the course itself is positioned as an introductory online class for broad access.
The public course offers a shareable certificate via Coursera. Johns Hopkins also runs credit-bearing and certificate programmes elsewhere in the university, but the psychedelic course itself is presented as an online class rather than a professional licensure or therapist certification pathway.
Johns Hopkins does not publish a single programme price for its psychedelic education offering on its own site. The Coursera course sits behind Coursera’s paid certificate model, with a free-trial or financial-aid route where available; the exact fee is set by Coursera at the point of enrolment.
Learners receive an online course completion experience with a shareable certificate through Coursera. The learning outcome is a grounded understanding of psychedelic history, neuroscience, clinical trials, therapeutic promise, risks, bioethical issues, and current debates in psychedelic medicine.
Published Papers
5
Trial Involvement
22
Distinct Focus Topics
0
Latest Publication
Mar 10, 2026
Psilocybin or Nicotine Patch for Smoking Cessation A Pilot Randomized Clinical Trial
JAMA Network Open - Mar 10, 2026
Pilot study of psilocybin in patients with post-treatment lyme disease
Scientific Reports - Feb 25, 2026
Psychedelic medicine: mechanisms, evidence, and translation to practice
BMJ - Feb 23, 2026
Psychiatry Research - Feb 13, 2026
Psychedelic Medicine - Feb 5, 2026
Philanthropic Funders
Gift to support psilocybin research for anorexia nervosa
Jan 1, 2022
undisclosed
Funders at Johns Hopkins Shape The Future of Psychedelic Research - Lucid NewsSupport for the Religious Leaders / clergy psilocybin study
Jan 1, 2016
undisclosed
Funders at Johns Hopkins Shape The Future of Psychedelic Research - Lucid NewsPartial funding of the 2016 study on challenging psilocybin experiences
Jan 1, 2016
undisclosed
Council on Spiritual Practices - WikipediaFirst LSD treatment study in ~50 years — chronic back pain in patients who misuse opioids
Jan 1, 2022
undisclosed
Heffter Research Institute 2022 NewsletterProfessorship and long-term research support
Reference points selected from shared training modalities, learner audience, level, delivery format, pricing, and location.
What the 36 registered trials Johns Hopkins University sponsors or participates in look like when you line them up. Counts come from Blossom’s trial records as of July 2026.
Registered trials by recorded study-start year; 5 earlier trials began before 2012. Click a year for the running total.
Don't read as total research effort: only registered trials with a recorded start date are counted (36 of 36 tracked). Recent years under-count because of registration lag; striped bars are still filling in or are planned starts.
Registry status of all 36 Johns Hopkins University trials Blossom tracks. Orange marks trials recruiting or opening.
Don't read stopped trials as failures: trials end early for funding, recruitment, and strategy reasons too. Status is as last synced from the registry; some 'recruiting' trials may already have finished.
Trials per primary indication. Orange marks the largest research focus.
Don't read shares as adding to 100%: a trial with several primary indications counts once per indication. Trial volume signals research attention, not evidence quality.
Trials per compound. Orange marks the most-studied compound.
Don't read shares as adding to 100%: a trial testing several compounds counts once per compound, and placebo comparator arms are not shown. Trial volume signals research attention, not evidence quality.